Spexis

Polyphor is a swiss pharma company focusing on the discovery and development of macrocycle drugs addressing high unmet medical needs.In December 2021, Polyphor AG and EnBiotix Inc had announced the merger. Later that month, Polyphor AG and EnBiotix Inc had closed the merger of the two companies with the new name of the combined company Spexis AG.In August 2020, Polyphor entered into an exclusive licensing agreement for balixafortide in China with Fosun Pharma. Polyphor would receive $15 million upfront, $148 million milestones and mid-teen royalties.In April 2023, Spexis AG finalized a capital commitment from SPRIM Global Investments (SGI) totaling USD 4.5 million in the form of secured.In July 2020, Polyphor entered into an equity-linked financing arrangement with IRIS to raise a gross amount of up to CHF 19.3 million (US $20.9818 million) over the period of two years.In September 2018, Novo Holdings A/S had committed to invest CHF 6.8 million (US $ 6.987